First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
COVID-19
Osimertinib
epidermal growth factor receptor (EGFR)
lung cancer
survival
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
received:
08
02
2023
accepted:
04
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
The FLAURA trial demonstrated improved overall survival (OS) with first-line osimertinib for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). We studied the efficacy and safety of osimertinib in a cohort treated during the coronavirus disease 2019 (COVID-19) pandemic. Patients diagnosed with EGFR-mutated advanced NSCLC between 11 March 2020 to 31 December 2021 who received first-line osimertinib in British Columbia, Canada were identified retrospectively. Kaplan-Meier curves of OS and progression-free survival (PFS) from the start of osimertinib were plotted. The associations of baseline characteristics with PFS, and development of pneumonitis or dose reductions due to toxicity with OS were evaluated with hazard ratios estimated using univariable and multivariable Cox models. The cohort comprised 231 individuals. 58.7% of patients with In a cohort receiving first-line osimertinib during the COVID-19 pandemic, ECOG PS ≥2 was observed in nearly half of patients at treatment initiation contributing to a median OS shorter than in FLAURA. The incidence of severe adverse events was low and dose reduction for drug toxicity did not impact OS. Identifying and reducing barriers to the diagnosis of NSCLC during the COVID-19 pandemic are required.
Sections du résumé
Background
UNASSIGNED
The FLAURA trial demonstrated improved overall survival (OS) with first-line osimertinib for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). We studied the efficacy and safety of osimertinib in a cohort treated during the coronavirus disease 2019 (COVID-19) pandemic.
Methods
UNASSIGNED
Patients diagnosed with EGFR-mutated advanced NSCLC between 11 March 2020 to 31 December 2021 who received first-line osimertinib in British Columbia, Canada were identified retrospectively. Kaplan-Meier curves of OS and progression-free survival (PFS) from the start of osimertinib were plotted. The associations of baseline characteristics with PFS, and development of pneumonitis or dose reductions due to toxicity with OS were evaluated with hazard ratios estimated using univariable and multivariable Cox models.
Results
UNASSIGNED
The cohort comprised 231 individuals. 58.7% of patients with
Conclusions
UNASSIGNED
In a cohort receiving first-line osimertinib during the COVID-19 pandemic, ECOG PS ≥2 was observed in nearly half of patients at treatment initiation contributing to a median OS shorter than in FLAURA. The incidence of severe adverse events was low and dose reduction for drug toxicity did not impact OS. Identifying and reducing barriers to the diagnosis of NSCLC during the COVID-19 pandemic are required.
Identifiants
pubmed: 37577326
doi: 10.21037/tlcr-23-81
pii: tlcr-12-07-1454
pmc: PMC10413024
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1454-1465Informations de copyright
2023 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-81/coif). PTT receives writing and royalty fees from UpToDate, Wolters Kluwer Health Publishing. SY has received consulting fees from Amgen, AstraZeneca, Bayer, Incyte, and Roche. DK has received a grant from the BC Cancer Foundation (Grant No. F22-05558) to support this manuscript and has received unrestricted educational grants from AstraZeneca and speaker honoraria from Merck and Bristol-Myers Squibb. The other authors have no conflicts of interest to declare.
Références
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
JCO Oncol Pract. 2020 Sep;16(9):579-586
pubmed: 32453656
Oncotarget. 2017 Dec 8;9(4):4637-4646
pubmed: 29435131
Eur J Cancer. 2021 Dec;159:144-153
pubmed: 34749119
Lung Cancer. 2014 May;84(2):196-202
pubmed: 24629638
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Br J Cancer. 2012 Oct 9;107(8):1220-6
pubmed: 22996611
Oncologist. 2022 Mar 4;27(2):87-e115
pubmed: 35641222
J Thorac Oncol. 2020 Jan;15(1):138-143
pubmed: 31605792
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Oncologist. 2022 Nov 3;27(11):903-e834
pubmed: 36181763
Clin Lung Cancer. 2015 Mar;16(2):144-151.e1
pubmed: 25454007
Lung Cancer. 2021 Apr;154:142-145
pubmed: 33667719
CMAJ Open. 2019 Feb 25;7(1):E117-E123
pubmed: 30808631
Ann Oncol. 2002 Jul;13(7):1087-93
pubmed: 12176788
Lancet Oncol. 2022 May;23(5):587-600
pubmed: 35397210
Ann Oncol. 2013 Sep;24(9):2371-6
pubmed: 23723294
Eur J Cancer. 2017 Nov;85:95-105
pubmed: 28892778
BJGP Open. 2020 Oct 27;4(4):
pubmed: 32900708
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
J Thorac Oncol. 2008 Feb;3(2):125-9
pubmed: 18303431
Chest. 2022 Nov;162(5):1188-1198
pubmed: 35661746
Invest New Drugs. 2022 Apr;40(2):430-437
pubmed: 34807331
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Cancer Treat Rev. 2022 Nov;110:102452
pubmed: 35998515
J Natl Cancer Inst. 2017 Jun 1;109(6):
pubmed: 28376144
Cancer Manag Res. 2021 Nov 20;13:8695-8705
pubmed: 34849025